Free Trial

Terrance Mcguire Sells 75,776 Shares of Invivyd, Inc. (NASDAQ:IVVD) Stock

Invivyd logo with Medical background

Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) Director Terrance Mcguire sold 75,776 shares of the stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $0.45, for a total value of $34,099.20. Following the completion of the transaction, the director now owns 3,492,498 shares of the company's stock, valued at $1,571,624.10. This trade represents a 2.12 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Terrance Mcguire also recently made the following trade(s):

  • On Thursday, December 26th, Terrance Mcguire sold 83,817 shares of Invivyd stock. The stock was sold at an average price of $0.54, for a total transaction of $45,261.18.
  • On Friday, December 20th, Terrance Mcguire sold 119,805 shares of Invivyd stock. The shares were sold at an average price of $0.42, for a total transaction of $50,318.10.
  • On Wednesday, December 18th, Terrance Mcguire sold 74,764 shares of Invivyd stock. The stock was sold at an average price of $0.47, for a total transaction of $35,139.08.
  • On Monday, December 16th, Terrance Mcguire sold 65,359 shares of Invivyd stock. The shares were sold at an average price of $0.47, for a total value of $30,718.73.
  • On Wednesday, December 11th, Terrance Mcguire sold 160,400 shares of Invivyd stock. The stock was sold at an average price of $0.59, for a total value of $94,636.00.
  • On Monday, December 9th, Terrance Mcguire sold 150,000 shares of Invivyd stock. The shares were sold at an average price of $0.61, for a total value of $91,500.00.

Invivyd Price Performance

NASDAQ:IVVD traded up $0.02 during midday trading on Thursday, reaching $0.53. The stock had a trading volume of 870,708 shares, compared to its average volume of 667,876. The stock has a market capitalization of $63.44 million, a P/E ratio of -0.27 and a beta of 0.53. Invivyd, Inc. has a 1-year low of $0.40 and a 1-year high of $5.20. The firm's fifty day simple moving average is $0.74 and its 200-day simple moving average is $0.99.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the stock. Morgan Stanley reduced their target price on shares of Invivyd from $9.50 to $3.55 and set an "overweight" rating for the company in a research note on Wednesday, November 20th. HC Wainwright reduced their price objective on shares of Invivyd from $15.00 to $10.00 and set a "buy" rating for the company in a research note on Wednesday, November 20th. EF Hutton Acquisition Co. I raised shares of Invivyd to a "strong-buy" rating in a research report on Wednesday, October 30th. Finally, D. Boral Capital reiterated a "buy" rating and set a $9.00 price target on shares of Invivyd in a research note on Thursday, November 21st. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Invivyd presently has an average rating of "Buy" and a consensus price target of $7.89.

Get Our Latest Research Report on Invivyd

Institutional Investors Weigh In On Invivyd

Hedge funds and other institutional investors have recently made changes to their positions in the business. Proficio Capital Partners LLC bought a new stake in Invivyd during the 3rd quarter valued at approximately $27,000. XTX Topco Ltd grew its stake in shares of Invivyd by 68.1% in the second quarter. XTX Topco Ltd now owns 37,938 shares of the company's stock worth $42,000 after acquiring an additional 15,376 shares during the last quarter. SG Americas Securities LLC increased its position in Invivyd by 198.6% during the second quarter. SG Americas Securities LLC now owns 37,893 shares of the company's stock worth $42,000 after acquiring an additional 25,201 shares during the period. Cornercap Investment Counsel Inc. acquired a new position in Invivyd during the 2nd quarter valued at $86,000. Finally, Rhumbline Advisers boosted its holdings in Invivyd by 4,434.1% in the 2nd quarter. Rhumbline Advisers now owns 84,017 shares of the company's stock valued at $92,000 after purchasing an additional 82,164 shares during the period. 70.36% of the stock is owned by institutional investors and hedge funds.

Invivyd Company Profile

(Get Free Report)

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.

Further Reading

Insider Buying and Selling by Quarter for Invivyd (NASDAQ:IVVD)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Invivyd Right Now?

Before you consider Invivyd, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Invivyd wasn't on the list.

While Invivyd currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Goldman Sachs’ 2025 Market Outlook: Top 3 Stock Picks
7 Stocks to Benefit From Trump’s Tariffs in 2025
Investing in Quantum Computing: Is Rigetti the Stock to Watch?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines